Equillium, Inc. SEC filings EQ
Equillium, Inc. has 465 filings in SEC EDGAR's recent list, going back to Aug 3, 2018. Its latest annual report, Form ARS, was filed on Apr 15, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 26, 2026 (unregistered share sale, regulation fd disclosure, other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Apr 16, 2026 | — |
| CORRESP | Letter to the SEC | Apr 14, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 13, 2026 | — |
| EFFECT | Filing | Mar 25, 2026 | — |
| CORRESP | Letter to the SEC | Mar 23, 2026 | — |
| EFFECT | Filing | Sep 18, 2025 | — |
| CORRESP | Letter to the SEC | Sep 16, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 16, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 11, 2025 | — |
| CORRESP | Letter to the SEC | Sep 11, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 8, 2025 | — |
| DEFR14A | Filing | Apr 30, 2025 | — |
| RW | Filing | Feb 23, 2023 | — |
| EFFECT | Filing | Jan 18, 2023 | — |
| CORRESP | Letter to the SEC | Jan 13, 2023 | — |
| UPLOAD | Letter from the SEC | Jan 12, 2023 | — |
| 425 | Filing | Dec 15, 2022 | — |
| 425 | Filing | Dec 6, 2022 | — |
| 425 | Filing | Dec 6, 2022 | — |
| 425 | Filing | Nov 14, 2022 | — |
| EFFECT | Filing | Nov 10, 2022 | — |
| CORRESP | Letter to the SEC | Nov 9, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 1, 2022 | — |
| 425 | Filing | Sep 28, 2022 | — |
| 425 | Filing | Sep 27, 2022 | — |
| 425 | Filing | Sep 26, 2022 | — |
| 425 | Filing | Sep 7, 2022 | — |
| 425 | Filing | Sep 6, 2022 | — |
| EFFECT | Filing | Apr 7, 2020 | — |
| CORRESP | Letter to the SEC | Apr 3, 2020 | — |
| UPLOAD | Letter from the SEC | Apr 2, 2020 | — |
| EFFECT | Filing | Nov 25, 2019 | — |
| CORRESP | Letter to the SEC | Nov 21, 2019 | — |
| UPLOAD | Letter from the SEC | Nov 20, 2019 | — |
| CERT | Filing | Oct 12, 2018 | — |
| CT ORDER | Filing | Oct 12, 2018 | — |
| EFFECT | Filing | Oct 11, 2018 | — |
| CORRESP | Letter to the SEC | Oct 9, 2018 | — |
| CORRESP | Letter to the SEC | Oct 9, 2018 | — |
| 8-A12B | Filing | Oct 5, 2018 | — |
| CORRESP | Letter to the SEC | Oct 2, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 1, 2018 | — |
| CORRESP | Letter to the SEC | Sep 28, 2018 | — |
| UPLOAD | Letter from the SEC | Sep 27, 2018 | — |
| CORRESP | Letter to the SEC | Sep 24, 2018 | — |
| CORRESP | Letter to the SEC | Sep 17, 2018 | — |
| UPLOAD | Letter from the SEC | Sep 17, 2018 | — |
| DRSLTR | Filing | Aug 30, 2018 | — |
| DRS/A | Filing | Aug 30, 2018 | — |
| UPLOAD | Letter from the SEC | Aug 28, 2018 | — |
| DRS | Filing | Aug 3, 2018 | — |
Showing 51 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- EQ (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- La Jolla, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1746466
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.